Join
Live feed
·
PRReleasevia Quantisnow
Wave Life Sciences Ltd. logo

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

ByQuantisnow·Wall Street's wire, on your screen.
WVE· Wave Life Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WVE (Wave Life Sciences Ltd.) and more on Quantisnow.